TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Stocks slip on China growth jitters
  2. Coal gathering opens with dour assessment, political vitriol
  3. Balancing gas pipeline expansion, environmental unease a problem in Pa.
  4. Symposiums to spotlight Pittsburgh’s role as an energy powerhouse
  5. Hospitals turn to technology to tear down language barriers with patients
  6. More companies embrace exchanges to curb health care costs
  7. MarksJarvis: Benefits, not just pay, hit the skids
  8. UPMC buying New Castle-based Jameson Health System
  9. Komando: It’s possible to keep your info safe online
  10. Pa. unemployment rate rises to 5.8 percent
  11. Getting into executive pipeline may require schmoozing
Subscribe today! Click here for our subscription offers.